Watch LXEO. Know when insiders buy.
One email the day a filing lands. Free.
LXEO
Lexeo Therapeutics, Inc.
4.20
+0.02 +0.48%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $344.6MP/E —DIV YIELD —FCF YIELD -25.74%REV TTM —NET INCOME −$87.3MNET CASH —52W 4.13 – 10.63SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$28M | −$25.9M | — | -0.30 | −$17.6M | $7K | −$17.6M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$22.3M | −$20.2M | — | -0.25 | −$21.1M | $35K | −$21.2M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$23.1M | −$21M | — | -0.14 | −$20.1M | $0 | −$20.1M | Aug 12 |
| Q3 2025 · Sep 30 | — | — | — | −$21.6M | −$20.3M | — | -0.33 | −$29.5M | $289K | −$29.8M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$30.7M | −$26.1M | — | -0.60 | −$27.2M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$33.8M | −$32.7M | — | -0.99 | −$21.7M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$27.4M | −$25.9M | — | -0.78 | −$28.3M | $0 | −$28.3M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$31.5M | −$29.5M | — | -0.89 | −$17.8M | $83K | −$17.9M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$23.6M | −$21.2M | — | -0.64 | −$20.2M | $213K | −$20.4M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$23.3M | −$21.7M | — | -0.77 | −$14.9M | $185K | −$15.1M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$15M | −$14.2M | — | 19.84 | −$14M | $73K | −$14.1M | Mar 24 |
| Q3 2023 · Sep 30 | — | — | — | −$20.3M | −$20.1M | — | -12.36 | −$13.9M | $3K | −$14M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$109.3M | −$100M | — | -1.86 | −$98.6M | $397K | −$99M | — | — |
| FY2024 · to Dec 31 | — | — | −$105.8M | −$98.3M | — | -3.09 | −$81.2M | $481K | −$81.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$68.5M | −$66.4M | — | -12.40 | −$59.5M | $115K | −$59.6M | — | — |
| FY2022 · to Dec 31 | $654K | — | −$60.5M | −$59.3M | -9063.8% | -36.36 | −$54.6M | $672K | −$55.2M | — | — |
Every number comes from Lexeo Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.